Cubist Systematic Strategies LLC Acquires New Position in Neurocrine Biosciences, Inc. (NBIX)

Cubist Systematic Strategies LLC acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,200 shares of the company’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors have also modified their holdings of NBIX. Northern Trust Corp grew its stake in Neurocrine Biosciences by 3.3% during the 1st quarter. Northern Trust Corp now owns 483,801 shares of the company’s stock valued at $40,122,000 after purchasing an additional 15,395 shares in the last quarter. GSA Capital Partners LLP bought a new position in Neurocrine Biosciences during the 1st quarter worth approximately $202,000. Principal Financial Group Inc. lifted its holdings in Neurocrine Biosciences by 1.6% during the 1st quarter. Principal Financial Group Inc. now owns 78,956 shares of the company’s stock worth $6,547,000 after buying an additional 1,234 shares during the last quarter. Allianz Asset Management GmbH lifted its holdings in Neurocrine Biosciences by 13.1% during the 1st quarter. Allianz Asset Management GmbH now owns 396,100 shares of the company’s stock worth $32,849,000 after buying an additional 45,775 shares during the last quarter. Finally, Lisanti Capital Growth LLC lifted its holdings in Neurocrine Biosciences by 32.5% during the 1st quarter. Lisanti Capital Growth LLC now owns 11,205 shares of the company’s stock worth $929,000 after buying an additional 2,750 shares during the last quarter.

A number of research analysts have commented on NBIX shares. Cantor Fitzgerald started coverage on Neurocrine Biosciences in a report on Wednesday, August 22nd. They set an “overweight” rating and a $150.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $162.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, August 1st. Oppenheimer set a $128.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, July 31st. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday, July 27th. Finally, ICAP reduced their target price on Neurocrine Biosciences from $140.00 to $128.00 and set an “outperform” rating on the stock in a report on Tuesday, September 4th. One research analyst has rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $122.22.

In related news, insider Dimitri E. Grigoriadis sold 23,022 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $110.00, for a total value of $2,532,420.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.

Shares of NASDAQ NBIX opened at $112.27 on Tuesday. The company has a market capitalization of $11.12 billion, a P/E ratio of -69.30, a P/E/G ratio of 38.11 and a beta of 0.55. Neurocrine Biosciences, Inc. has a 12-month low of $57.71 and a 12-month high of $126.98. The company has a debt-to-equity ratio of 1.00, a quick ratio of 9.19 and a current ratio of 9.19.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.11. The business had revenue of $96.90 million for the quarter, compared to the consensus estimate of $84.11 million. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The business’s revenue was up 1428.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.68) EPS. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 0.15 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C.

Further Reading: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply